

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-293001	Application No. 09/668,196
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Stephen J. Russell et al.	
		Filing Date September 22, 2000	Group Art Unit 1648

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No
	AB						

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>							
Examiner Initial	Desig. ID	Document					
	AC	Heinzerling et al., "Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells," <i>Blood</i> , 106:2287-2294 (2005)					
	AD	Myers et al., "Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer." <i>Cancer Gene Therapy</i> , 12:593-599 (2005)					
	AE	Ong et al., "Oncolytic Measles Virus Targets High CD46 Expression on Multiple Myeloma Cells," Manuscript submitted for publication in <i>Experimental Hematology</i> on November 30, 2005 (27 pages)					
	AF	Peng et al., "Systemic therapy of myeloma xenografts by an attenuated measles virus," <i>Blood</i> , 98:2002-2007 (2001)					
	AG	Peng et al., "Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus," <i>Cancer Research</i> , 62:4656-4662 (2002)					

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	